Pfizer Seeks Approval for New Lyme Disease Vaccine

Pfizer has announced plans to seek regulatory approval for a new Lyme disease vaccine, which would be the first available on the market in over two decades. The vaccine's path to approval in the United States may face challenges.

This is partly due to the historical context of previous Lyme vaccines and the expressed views of Robert F. Kennedy Jr., who has discussed his personal experiences with Lyme disease and raised questions regarding vaccine safety and the disease's origins.

The Expanding Threat of Lyme Disease

Lyme disease, caused by the bacterium Borrelia burgdorferi and spread by blacklegged ticks, is a significant and growing public health issue.

Approximately 476,000 individuals are diagnosed and treated for Lyme disease each year in the U.S.

The geographical areas where the disease is prevalent have been expanding, a trend attributed to factors such as climate change and altered land use. Symptoms can include fever, fatigue, and a characteristic skin rash. If left untreated, the infection can affect joints, the heart, and the nervous system. While most early cases are effectively treated with antibiotics, some patients develop long-lasting symptoms, known as post-treatment Lyme disease syndrome.

A Troubled Past: The Lymerix Experience

A previous Lyme disease vaccine, Lymerix by GSK, received FDA approval in 1998. However, its market presence was brief. Government bodies provided lukewarm endorsements, and initial recommendations were cautious, limiting its approved age range and noting the need for three doses over a year for approximately 75% protection. The CDC's Advisory Committee on Immunization Practices (ACIP) issued a "should be considered" recommendation rather than a stronger, routine endorsement.

After its market release, concerns emerged, including unproven claims that the vaccine caused arthritis. Despite an FDA advisory panel concluding in 2001 that no association existed, lawsuits accumulated.

GSK withdrew Lymerix in 2002, citing low demand.

Another vaccine candidate with promising trial results was not submitted for approval following this experience.

Pfizer and Valneva's Novel Approach

The new vaccine, developed by Pfizer and Valneva, utilizes a similar approach to Lymerix, targeting a surface protein of the Lyme bacteria to stimulate antibody production. These antibodies aim to neutralize the bacteria within the tick's gut upon a blood meal, preventing human infection.

Clinical trial results indicated that four doses administered over two seasons reduced Lyme disease cases by approximately 75%, similar to Lymerix's efficacy.

Key differences include the new vaccine's protection against six prevalent surface protein types in North America and Europe, compared to Lymerix's one. Additionally, the new vaccine was designed to exclude a portion of the surface protein that had previously raised a theoretical risk of arthritis.

Navigating Acceptance: Concerns and Alternatives

Acceptance of a new Lyme disease vaccine faces scrutiny. Dr. Linden Hu, co-director of the Tufts University Lyme Disease Initiative, stated that a four-dose vaccine with 75% efficacy "might be a difficult sell." Advocacy groups like LymeDisease.org express reservations, citing the past experience with Lymerix and unproven patient claims of adverse effects.

Lorraine Johnson, CEO of LymeDisease.org, noted that the vaccine only protects against Lyme disease, not other pathogens transmitted by the same ticks.

This could lead to a "false sense of complacency" among vaccinated individuals.

Research is ongoing for broader prevention methods, including a pill designed to kill ticks after biting and vaccines for mice to reduce transmission.

Robert F. Kennedy Jr. and the Lyme Debate

Robert F. Kennedy Jr. has publicly recounted his personal experiences with Lyme disease and its impact on his family. As a potential Secretary of the US Department of Health and Human Services (HHS), he has vowed to address Lyme disease. However, he has also promoted theories, which disease ecologist Dr. Richard Ostfeld described as "destructive and clearly false," suggesting Lyme disease may have been a bioweapon engineered by the US government.

Historically, Kennedy has expressed skepticism regarding vaccines. While advocating for Lyme disease solutions, he has not specifically emphasized vaccination as a primary approach within his public statements on the topic. At an HHS roundtable on Lyme disease, mentions of vaccines as a solution primarily came from invited lawmakers. HHS spokesperson Andrew Nixon stated that HHS "supports rigorous, gold-standard science to better understand, prevent, and treat Lyme disease" but did not directly confirm support for vaccines as part of prevention efforts.